MiMedx Group, Inc. (NASDAQ:MDXG) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC trimmed its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 81.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,405 shares of the company’s stock after selling 27,390 shares during the quarter. Lazard Asset Management LLC’s holdings in MiMedx Group were worth $61,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. IMG Wealth Management Inc. acquired a new stake in shares of MiMedx Group in the fourth quarter valued at about $28,000. Van ECK Associates Corp acquired a new position in shares of MiMedx Group during the fourth quarter valued at approximately $40,000. Tower Research Capital LLC TRC boosted its holdings in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after buying an additional 2,837 shares in the last quarter. AlphaQuest LLC purchased a new position in MiMedx Group in the 4th quarter worth about $88,000. Finally, Savant Capital LLC acquired a new stake in MiMedx Group during the 4th quarter valued at $100,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now directly owns 440,178 shares in the company, valued at approximately $3,473,004.42. This represents a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph H. Capper acquired 200,000 shares of the business’s stock in a transaction dated Friday, May 2nd. The shares were bought at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the transaction, the chief executive officer now directly owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.70% of the stock is owned by company insiders.

MiMedx Group Price Performance

MiMedx Group stock opened at $6.63 on Monday. The firm has a market capitalization of $979.26 million, a P/E ratio of 12.05 and a beta of 1.85. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business has a 50-day moving average of $7.09 and a 200-day moving average of $8.17. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The company had revenue of $88.21 million during the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, equities analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on MDXG shares. Wall Street Zen cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.